Century Therapeutics, Inc. expanded its Board of Directors from six to seven members and appointed Joseph Truitt as a Class I director effective September 9, 2026. Mr. Truitt, currently CEO of iECURE, Inc., will serve on the Compensation Committee and receive an initial option grant for 148,000 shares vesting over 36 months plus an annual cash retainer of $40,000. The appointment supports leadership as the company advances its iPSC-derived cell therapy pipeline toward key milestones in 2026. Century Therapeutics is a biotechnology company developing induced pluripotent stem cell-derived therapies for autoimmune diseases and cancer.

Century Therapeutics, Inc. reported financial results for the quarter ended June 30, 2026, announcing a net loss of $34.6 million and cash reserves of $197.2 million as of June 30, 2026, providing an estimated operating runway into the first quarter of 2029. The company completed a pre-IND meeting with the FDA for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, aligning on nonclinical data and trial design while maintaining an IND submission target for the fourth quarter of 2026. Additionally, Century remains on track to initiate clinical trials in 2026 for CNTY-308, a CD19-targeted CAR-iT cell therapy for B-cell-mediated autoimmune diseases. The biotechnology company develops induced pluripotent stem cell-derived therapies for autoimmune diseases and cancer.

Century Therapeutics, Inc. entered into an Amended and Restated Employment Agreement with Chief Scientific Officer Chad Cowan, Ph.D., effective June 15, 2026. Under the terms of part-time status, Dr. Cowan will receive a reduced annual salary of $296,150 and remains eligible for a pro-rated performance-based target bonus. Century Therapeutics, Inc. is a biotechnology company focused on developing cell therapies for cancer and autoimmune diseases.

At the 2026 Annual Meeting of Stockholders, Century Therapeutics, Inc. stockholders approved an amendment to the Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 to 450,000,000. Alessandro Riva, M.D. and Han Lee, Ph.D., M.B.A. were elected to the Board of Directors. Century Therapeutics, Inc. is a biotechnology company focused on developing cell therapies for cancer and autoimmune diseases.

Century Therapeutics announced the presentation of preclinical data from its iPSC-derived cell therapy platform at the American Diabetes Association (ADA) 2026 Scientific Sessions held June 5-8, 2026.